Mr. Nielsen co-founded Bio-Path and has served as Bio-Path’s President, Chief Executive Officer, Chief Financial Officer/Treasurer and Chairman of the Board since 2008. At the time of Bio-Path’s establishment in 2007, Mr. Nielsen licensed technology and targets from The University of Texas, MD Anderson Cancer Center and coordinated preclinical development, optimization and manufacturing of Bio-Path’s lead drug candidate, prexigebersen. Since that time, Mr. Nielsen has led the clinical advancement of prexigebersen into Phase 2 studies, the introduction of additional pipeline candidates and the Company’s public market debut. Prior to co-founding Bio-Path, Mr. Nielsen worked with several other companies, leading turnarounds and developing and executing on strategies for growth. Mr. Nielsen previously served as a director of Synthecon, Inc., a company developing 3D cell culture technology. Before entering the biotechnology sector, Mr. Nielsen was a lieutenant in the U.S. Naval Nuclear Power program where he was director of the physics department and was employed at Ford Motor Company in product development. Mr. Nielsen has a broad background in senior management and has significant negotiating experience. He holds engineering, mathematics and M.B.A. finance degrees from the University of California at Berkeley.

Mr. Cleaver has served as chief financial officer of Porto Energy Corp., junior oil and gas exploration company listed on the Canadian Venture Exchange, since February 2011. Prior to his elevation to chief financial officer, Mr. Cleaver served as chief accounting officer. Mr. Cleaver served as corporate controller and then as vice president and chief accounting officer for BPZ Energy from October 2006 to mid-2010. Prior to joining BPZ, Mr. Cleaver was engaged as a consultant for a variety of public companies such as Rosetta Resources, Calpine Natural Gas and Index Oil and Gas. Mr. Cleaver is a Certified Public Accountant in the state of Texas and holds a Bachelor of Business Administration – Accounting from Texas A&M University.

Paul Aubert currently serves individuals and corporations through his private law practice. In addition, he serves as general counsel to four companies, including a developer of dental implant. Prior to launching his own practice, he served as general counsel of Pernix Therapeutics Holdings, Inc. (Nasdaq: PTX), a specialty pharmaceutical company. For the 13 years prior to joining Pernix, Mr. Aubert worked in the Corporate and Securities divisions of several law firms, including Weil, Gotshal & Manges and Andrews Kurth LLP, and Winstead PC, where he provided legal advice on general corporate matters as well as securities and M&A transactions to public and private companies. He received his Juris Doctor and MBA from Tulane University in New Orleans, Louisiana in 1996, and his Bachelor of Arts in history from Louisiana State University – Baton Rouge in 1990.

Douglas P. Morris is a co-founder of Bio-Path and a co-founding director. Mr. Morris has a number of administrative responsibilities, including working with retail broker/dealers in raising capital for small cap companies, and interfacing with existing shareholders. Mr. Morris has a Bachelor of Arts from Brigham Young University and is working towards a Master of Public Administration from the University of Southern California.

Ms. Sherwood was appointed to the Board on March 31, 2022. Since January 2017, Ms. Sherwood has been the owner of Scienta Communications, LLC, an independent communications consultancy established in 2010 to provide strategic public relations and corporate communications counsel to pre-commercial, public and private life sciences companies. In this capacity, she has provided strategic communications and crisis management counsel to biotechnology and medical device executives. On a day-to-day basis, she provides tactical support including development of materials and coordination of events, conference calls and webcasts, supports client milestones with media outreach and provides strategic counsel to enhance the company’s perception on Wall Street and in industry.

Earlier in her career, Ms. Sherwood managed corporate communications for The Liposome Company. During the subsequent decade, she worked at a series of global and boutique public and investor relations agencies where she provided support for companies pursuing a variety of indications including oncology. Through these combined experiences, Ms. Sherwood developed a general knowledge of the research and development process, and an understanding of the potential of delivery technologies to enhance oncology drug development.